Interaction of Nanomaterials with the Immune System: Role in Nanosafety and Nanomedicinenanomedicine
The immune system has the double role of maintaining tissue integrity and homeostasis and of protecting the organism from possible dangers, from invading pathogens to environmentally-borne dangerous chemicals. New chemicals recognisable by the immune system are engineered nanomaterials/ nanoparticle...
Saved in:
Superior document: | Frontiers Research Topics |
---|---|
: | |
Year of Publication: | 2018 |
Language: | English |
Series: | Frontiers Research Topics
|
Physical Description: | 1 electronic resource (177 p.) |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
993543929004498 |
---|---|
ctrlnum |
(CKB)4920000000094272 (oapen)https://directory.doabooks.org/handle/20.500.12854/50453 (EXLCZ)994920000000094272 |
collection |
bib_alma |
record_format |
marc |
spelling |
Paulo Bonan auth Interaction of Nanomaterials with the Immune System: Role in Nanosafety and Nanomedicinenanomedicine Interaction of Nanomaterials with the Immune System Frontiers Media SA 2018 1 electronic resource (177 p.) text txt rdacontent computer c rdamedia online resource cr rdacarrier Frontiers Research Topics The immune system has the double role of maintaining tissue integrity and homeostasis and of protecting the organism from possible dangers, from invading pathogens to environmentally-borne dangerous chemicals. New chemicals recognisable by the immune system are engineered nanomaterials/ nanoparticles, new agents in our environment that are becoming common due to their presence in many products, from constructions and building material (e.g., solar cells, pigments and paints, tiles and masonry materials) to daily products (e.g., food packaging, cosmetics, and cigarettes). Human beings can be accidentally exposed to engineered nanomaterials when these are released from products containing them or during production in workplaces. Furthermore, intentional exposure occurs in medicine, as engineered nanoparticles are used as tools for improving delivery of drugs and vaccines, vaccine adjuvants and contrast agents in therapeutic, preventive and diagnostic strategies. Nanoparticles that come in contact with the immune system after unintentional exposure need to be eliminated from the organism as they represent a potential threat. In this case, however, due to their peculiar characteristics of size, shape, surface charge and persistence, nanoparticles may elicit undesirable reactions and have detrimental effects on the immune system, such as cytotoxicity, inflammation, anaphylaxis, immunosuppression. Conversely, nanomedicines need to escape immune recognition/elimination and must persist in the organism long enough for reaching their target and exerting their beneficial effects. Immune cells and molecules at the body surface (airway and digestive mucosae, skin) are the first that come in contact with nanomaterials upon accidental exposure, while immune effectors in blood are those that more easily come in contact with nanomedical products. Thus, evaluating the interaction of the immune system with nanoparticles/nanomaterials is a topic of key importance both in nanotoxicology and in nanomedicine. Immuno-nanosafety studies consider both accidental exposure to nanoparticles, which may occur by skin contact, ingestion or inhalation (at doses and with a frequency that are not known), and medical exposure, which takes place with a defined administration schedule (route, dose, frequency). Many studies focus on the interaction between the immune system and nanoparticles that, for medical purposes, have been specifically modified to stimulate immunity or to avoid immune recognition, as in the case of vaccine carriers/adjuvants or drug delivery systems, respectively. The aims of this Research Topic is to provide an overview of recent strategies: 1.for assessing the immunosafety of engineered nanomaterials/nanoparticles, in particular in terms of activation of inflammatory responses, such as complement activation and allergic reactions, based on the nanomaterial intrinsic characteristics and on the possible carry-over of bioactive contaminants such as LPS. Production of new nanoparticles taking into account their effects on immune responses, in order to avoid undesirable effects on one hand, and to design particles with desirable effects for medical applications on the other hand; 2.for designing more effective nanomedicines by either avoiding or exploiting their interaction with the immune systems, with particular focus on cancer diagnosis and therapy, and vaccination. This collection of articles gives a comprehensive view of the state-of-the-art of the interaction of nanoparticles with the immune system from the two perspectives of safety and medical use, and aims at providing immunologists with the relevant knowledge for designing improved strategies for immunologically safe nanomaterial applications. English anti-tumor therapy innate immunity Immunomodulation immune system nanomaterials Inflammation Vaccines complement Nanomedicine 2-88945-387-1 Lucio R. C. Castellano auth Paola Italiani auth Diana Boraschi auth Eliton S. Medeiros auth |
language |
English |
format |
eBook |
author |
Paulo Bonan |
spellingShingle |
Paulo Bonan Interaction of Nanomaterials with the Immune System: Role in Nanosafety and Nanomedicinenanomedicine Frontiers Research Topics |
author_facet |
Paulo Bonan Lucio R. C. Castellano Paola Italiani Diana Boraschi Eliton S. Medeiros |
author_variant |
p b pb |
author2 |
Lucio R. C. Castellano Paola Italiani Diana Boraschi Eliton S. Medeiros |
author2_variant |
l r c c lrcc p i pi d b db e s m esm |
author_sort |
Paulo Bonan |
title |
Interaction of Nanomaterials with the Immune System: Role in Nanosafety and Nanomedicinenanomedicine |
title_full |
Interaction of Nanomaterials with the Immune System: Role in Nanosafety and Nanomedicinenanomedicine |
title_fullStr |
Interaction of Nanomaterials with the Immune System: Role in Nanosafety and Nanomedicinenanomedicine |
title_full_unstemmed |
Interaction of Nanomaterials with the Immune System: Role in Nanosafety and Nanomedicinenanomedicine |
title_auth |
Interaction of Nanomaterials with the Immune System: Role in Nanosafety and Nanomedicinenanomedicine |
title_alt |
Interaction of Nanomaterials with the Immune System |
title_new |
Interaction of Nanomaterials with the Immune System: Role in Nanosafety and Nanomedicinenanomedicine |
title_sort |
interaction of nanomaterials with the immune system: role in nanosafety and nanomedicinenanomedicine |
series |
Frontiers Research Topics |
series2 |
Frontiers Research Topics |
publisher |
Frontiers Media SA |
publishDate |
2018 |
physical |
1 electronic resource (177 p.) |
isbn |
2-88945-387-1 |
illustrated |
Not Illustrated |
work_keys_str_mv |
AT paulobonan interactionofnanomaterialswiththeimmunesystemroleinnanosafetyandnanomedicinenanomedicine AT luciorccastellano interactionofnanomaterialswiththeimmunesystemroleinnanosafetyandnanomedicinenanomedicine AT paolaitaliani interactionofnanomaterialswiththeimmunesystemroleinnanosafetyandnanomedicinenanomedicine AT dianaboraschi interactionofnanomaterialswiththeimmunesystemroleinnanosafetyandnanomedicinenanomedicine AT elitonsmedeiros interactionofnanomaterialswiththeimmunesystemroleinnanosafetyandnanomedicinenanomedicine AT paulobonan interactionofnanomaterialswiththeimmunesystem AT luciorccastellano interactionofnanomaterialswiththeimmunesystem AT paolaitaliani interactionofnanomaterialswiththeimmunesystem AT dianaboraschi interactionofnanomaterialswiththeimmunesystem AT elitonsmedeiros interactionofnanomaterialswiththeimmunesystem |
status_str |
n |
ids_txt_mv |
(CKB)4920000000094272 (oapen)https://directory.doabooks.org/handle/20.500.12854/50453 (EXLCZ)994920000000094272 |
carrierType_str_mv |
cr |
hierarchy_parent_title |
Frontiers Research Topics |
is_hierarchy_title |
Interaction of Nanomaterials with the Immune System: Role in Nanosafety and Nanomedicinenanomedicine |
container_title |
Frontiers Research Topics |
author2_original_writing_str_mv |
noLinkedField noLinkedField noLinkedField noLinkedField |
_version_ |
1787548883659784192 |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>05084nam-a2200433z--4500</leader><controlfield tag="001">993543929004498</controlfield><controlfield tag="005">20231214133459.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr|mn|---annan</controlfield><controlfield tag="008">202102s2018 xx |||||o ||| 0|eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)4920000000094272</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(oapen)https://directory.doabooks.org/handle/20.500.12854/50453</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)994920000000094272</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Paulo Bonan</subfield><subfield code="4">auth</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Interaction of Nanomaterials with the Immune System: Role in Nanosafety and Nanomedicinenanomedicine</subfield></datafield><datafield tag="246" ind1=" " ind2=" "><subfield code="a">Interaction of Nanomaterials with the Immune System</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="b">Frontiers Media SA</subfield><subfield code="c">2018</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 electronic resource (177 p.)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Frontiers Research Topics</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The immune system has the double role of maintaining tissue integrity and homeostasis and of protecting the organism from possible dangers, from invading pathogens to environmentally-borne dangerous chemicals. New chemicals recognisable by the immune system are engineered nanomaterials/ nanoparticles, new agents in our environment that are becoming common due to their presence in many products, from constructions and building material (e.g., solar cells, pigments and paints, tiles and masonry materials) to daily products (e.g., food packaging, cosmetics, and cigarettes). Human beings can be accidentally exposed to engineered nanomaterials when these are released from products containing them or during production in workplaces. Furthermore, intentional exposure occurs in medicine, as engineered nanoparticles are used as tools for improving delivery of drugs and vaccines, vaccine adjuvants and contrast agents in therapeutic, preventive and diagnostic strategies. Nanoparticles that come in contact with the immune system after unintentional exposure need to be eliminated from the organism as they represent a potential threat. In this case, however, due to their peculiar characteristics of size, shape, surface charge and persistence, nanoparticles may elicit undesirable reactions and have detrimental effects on the immune system, such as cytotoxicity, inflammation, anaphylaxis, immunosuppression. Conversely, nanomedicines need to escape immune recognition/elimination and must persist in the organism long enough for reaching their target and exerting their beneficial effects. Immune cells and molecules at the body surface (airway and digestive mucosae, skin) are the first that come in contact with nanomaterials upon accidental exposure, while immune effectors in blood are those that more easily come in contact with nanomedical products. Thus, evaluating the interaction of the immune system with nanoparticles/nanomaterials is a topic of key importance both in nanotoxicology and in nanomedicine. Immuno-nanosafety studies consider both accidental exposure to nanoparticles, which may occur by skin contact, ingestion or inhalation (at doses and with a frequency that are not known), and medical exposure, which takes place with a defined administration schedule (route, dose, frequency). Many studies focus on the interaction between the immune system and nanoparticles that, for medical purposes, have been specifically modified to stimulate immunity or to avoid immune recognition, as in the case of vaccine carriers/adjuvants or drug delivery systems, respectively. The aims of this Research Topic is to provide an overview of recent strategies: 1.for assessing the immunosafety of engineered nanomaterials/nanoparticles, in particular in terms of activation of inflammatory responses, such as complement activation and allergic reactions, based on the nanomaterial intrinsic characteristics and on the possible carry-over of bioactive contaminants such as LPS. Production of new nanoparticles taking into account their effects on immune responses, in order to avoid undesirable effects on one hand, and to design particles with desirable effects for medical applications on the other hand; 2.for designing more effective nanomedicines by either avoiding or exploiting their interaction with the immune systems, with particular focus on cancer diagnosis and therapy, and vaccination. This collection of articles gives a comprehensive view of the state-of-the-art of the interaction of nanoparticles with the immune system from the two perspectives of safety and medical use, and aims at providing immunologists with the relevant knowledge for designing improved strategies for immunologically safe nanomaterial applications.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">anti-tumor therapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">innate immunity</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Immunomodulation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">immune system</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">nanomaterials</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Inflammation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Vaccines</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">complement</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Nanomedicine</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">2-88945-387-1</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lucio R. C. Castellano</subfield><subfield code="4">auth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Paola Italiani</subfield><subfield code="4">auth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Diana Boraschi</subfield><subfield code="4">auth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Eliton S. Medeiros</subfield><subfield code="4">auth</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-12-15 05:55:17 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2019-11-10 04:18:40 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5337541270004498&Force_direct=true</subfield><subfield code="Z">5337541270004498</subfield><subfield code="b">Available</subfield><subfield code="8">5337541270004498</subfield></datafield></record></collection> |